Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chen-Yen Lin

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
The Journal of Dermatological Treatment|December 3, 2020
Disease response and patient-reported outcomes among initiators of ixekizumabMona Shahriari, Ryan W Harrison, Russel Burge, et al.
Annals of the Rheumatic Diseases|August 25, 2016
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, et al.
Plos One|January 20, 2022
Deciphering the evolution of composite-type GSKIP in mitochondria and Wnt signaling pathwaysCheng-Yu Tsai, Shean-Jaw Chiou, Huey-Jiun Ko, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
International Journal of Molecular Sciences|January 26, 2019
Thioridazine Enhances P62-Mediated Autophagy and Apoptosis Through Wnt/β-Catenin Signaling Pathway in Glioma CellsCheng-Wei Chu, Huey-Jiun Ko, Chia-Hua Chou, et al.
Journal of the American Academy of Dermatology|April 29, 2020
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric Simpson, Robert Bissonnette, Lawrence F Eichenfield, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
The Journal of Dermatological Treatment|December 3, 2020
Disease response and patient-reported outcomes among initiators of ixekizumabMona Shahriari, Ryan W Harrison, Russel Burge, et al.
Annals of the Rheumatic Diseases|August 25, 2016
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, et al.
Plos One|January 20, 2022
Deciphering the evolution of composite-type GSKIP in mitochondria and Wnt signaling pathwaysCheng-Yu Tsai, Shean-Jaw Chiou, Huey-Jiun Ko, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
International Journal of Molecular Sciences|January 26, 2019
Thioridazine Enhances P62-Mediated Autophagy and Apoptosis Through Wnt/β-Catenin Signaling Pathway in Glioma CellsCheng-Wei Chu, Huey-Jiun Ko, Chia-Hua Chou, et al.
Journal of the American Academy of Dermatology|April 29, 2020
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric Simpson, Robert Bissonnette, Lawrence F Eichenfield, et al.
Pageof 5